Skip to content

A study on immunity after Covid 19 vaccine

Observational Study on Long-term Immunogenicity of COVID-19 vaccines in vaccine-naïve seronegative and seropositive participants

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/07/034663
Enrollment
200
Registered
2021-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Covishield: vaccine Control Intervention1: covaxin: vaccine

Sponsors

National Centre for Biological Science
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Permanent residents of the selected localities where community outreach is routine - Only one member from a household will be selected. - Either a) sero-negativity or b) sero-positivity to SARS-CoV-2 with or without a history of clinical illness suggestive of COVID-19 or confirmed COVID-19 in the past (either mild or moderate infection)

Exclusion criteria

Exclusion criteria: - Participant failure to consent. - Pregnancy, diabetes, chronic infection such as HIV or tuberculosis and immunocompromised patients (all by history) - Acute febrile illness in the participant at the time of the survey. - Active cancers or bleeding disorders - Individuals with a history of severe COVID-19 that required ventilation or received either convalescent plasma or monoclonal antibody treatments. - Any medical condition in the participant, which, in the judgment of the investigator, would interfere with protocol adherence.

Design outcomes

Primary

MeasureTime frame
- Difference in titers and rate of increase of plasma neutralizing antibody/glycoprotein-specific antibodies post vaccination between individuals seropositive and seronegative at baseline - Magnitude of binding antibody titers (RBD/spike, nucleocapsid) post vaccination in individuals seropositive and seronegative at baseline - Seroconversion rate and duration of antibodies in individuals sero-negative at baseline Timepoint: day 42 90 180 270

Secondary

MeasureTime frame
Difference in frequency of RBD/spike-reactive memory B cells post-vaccination between individuals seropositive and seronegative at baseline -Difference in positivity and magnitude of cytokine-producing T cells against spike peptides between individuals seropositive and seronegative at baselineTimepoint: day 42 90 180 270

Countries

India

Contacts

Public ContactDr Carolin Elizabeth George

Bangalore Baptist Hospital

carolinelizabethj@gmail.com9972156838

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026